Pfizer vaccine data released: 95% effective

• United Kingdom: no vaccine for those with "significant" allergic reactions.

  Pfizer: No serious alarms

• Cyber-Attack on Ema, Pfizer vaccine target

• Margaret, first patient in the world to receive Pfizer BioNTech vaccine.

  "Shakespeare" is the first man

• Great Britain ready to vaccinate: 800 thousand doses of Pfizer-BioNTech vaccine stored in secret

Share

December 10, 2020 The data of the

, which is 95% effective (with a range between 90.3% and 97.6%),

have been disclosed in the New England Journal of Medicine

.

The trial involved 43,548 people (people aged 16 or over), half of whom received the vaccine, identified by the initials BNT162b2, and half of the placebo (a substance devoid of active ingredients,

).

The safety for a median of 2 months was similar to that of other viral vaccines, "the article reads. The vaccine candidate showed" similar efficacy, generally between 90% and 100%, in subgroups defined by age, sex, ethnicity, body mass index and the presence of coexisting conditions. "

, mild to moderate

injection site,

were observed as side effects

.

The incidence of serious adverse events was low and similar in the vaccine and placebo groups. "

There is also an accompanying editorial in the journal that calls the results" impressive "and

" a triumph ".

: "It took decades to develop the majority of vaccines - the authors note - while in this case it is likely that within a year we will pass from conception to large-scale use". 

"Now vaccination, and immediately.

I told you to keep the bottle cool, and I was right ", writes on Twitter the virologist

, professor at the Vita-Salute San Raffaele University in Milan, posting an article in which - on the 'MedicalFacts' website - comments on results after being announced in the past few weeks.